報價延遲最少15分鐘:2025/11/16 13:19 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-8.31/--
|
|
企業價值
380.17M
|
| 資產負債 |
|
每股賬面淨值
12.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/16 13:19 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broadtherapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries. |
